Reimbursed Care Access in Kyrgyzstan

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorized medical use outside of approved clinical research. The Kyrgyz Criminal Code and implementing lists treat narcotic drugs and psychotropic substances as prohibited except where specially regulated by government authorisation; possession, manufacture or trafficking are subject to criminal penalties. #.

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorized medical use outside of approved clinical research. Criminal provisions criminalize manufacture, possession and distribution of narcotic and psychotropic substances unless explicitly regulated by government order. #.

There is no public, authoritative registry evidence identified in open government sources during this review that esketamine (Spravato or other esketamine formulations) has been granted a marketing authorisation or is part of a reimbursed mental‑health programme in the Kyrgyz Republic. Kyrgyz law strictly regulates circulation of psychotropic and narcotic medicines, and medicines containing controlled substances are subject to special prescription and dispensing rules administered by the Ministry of Health; draft revisions to prescription/dispensing rules have been under public discussion, indicating controlled distribution procedures for any narcotic/psychotropic medicines. Consequently, esketamine would only be accessible in Kyrgyzstan if provided under an authorised clinical trial or a special import/compassionate‑use pathway (no public evidence of routine national approval/reimbursement was found). #, #.

Ketamine is a controlled medicinal product in Kyrgyzstan that is used in health‑care settings (primarily as an anaesthetic and, in practice, by some clinicians for off‑label psychiatric indications). Public procurement records and tender listings show active procurement of ketamine by Kyrgyz entities (indicative of its recognised medical supply chain for hospitals/clinics). #.

Regulatory/coverage context: the Kyrgyz Criminal Code and secondary regulation reserve narcotic and psychotropic substances to controlled medical circulation when authorised; issuance and dispensing of such medicines are governed by Ministry of Health rules and special prescription/dispensing forms (recent Ministry of Health drafting activity confirms an active regulatory framework for prescription medicines containing controlled substances). Public reimbursement for ketamine‑based psychiatric care (e.g., ketamine infusion for depression) is not documented in available public sources; ketamine is procured by health institutions rather than being described in a nationally reimbursed psychedelic‑therapy programme, so psychiatric uses outside standard anaesthesia are most likely private/out‑of‑pocket or limited to research/clinical pilot programmes. #, #, #.

Practical implications: clinicians in Kyrgyzstan may lawfully use ketamine in authorised medical settings under prescription and institutional procurement; however, there is no publicly available evidence of structured public‑insurance reimbursement for ketamine when used for psychiatric indications (access therefore depends on institutional policy, private payment or research programmes).

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorised medical use outside of approved clinical research or tightly controlled import/exception processes. The Criminal Code frames broad prohibitions on psychotropic substances and allows the government to determine the official list of prohibited substances; no public evidence was found of a medical or reimbursed pathway for DMT. #.

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorised medical use outside of approved clinical research. No public legal or health‑system framework for medical access or reimbursement for 5‑MeO‑DMT was identified. #.

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorised medical use outside of approved clinical research. There is no public evidence of legal medical programmes or reimbursement for ibogaine in Kyrgyzstan. #.

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan (components such as DMT are controlled), with no authorised medical use outside of approved clinical research. Traditional/ceremonial use does not create a legal exception under current Kyrgyz law and could expose individuals to criminal liability. #.

Currently classified as a strictly controlled substance under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorised medical use outside of approved clinical research. No public health or reimbursement programme for mescaline exists in Kyrgyzstan. #.

Currently classified as a strictly controlled substance (or analogue/psychotropic substance) under national drug‑scheduling and criminal law in Kyrgyzstan, with no authorised medical use outside of approved clinical research. The criminal provisions and government lists are used to control novel psychoactive substances and analogues; there is no public pathway for medical access or reimbursement for 2C‑X family compounds. #.